NASDAQ:ZIOP ZIOPHARM Oncology (ZIOP) Stock Price, News & Analysis → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Free ZIOP Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$0.82▼$1.3952-Week Range N/AVolume2.13 million shsAverage Volume2.01 million shsMarket Capitalization$187.12 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get ZIOPHARM Oncology alerts: Email Address Ad Crypto 101 MediaSHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. About ZIOPHARM Oncology Stock (NASDAQ:ZIOP)ZIOPHARM Oncology, Inc. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of immuno-oncology platforms that leverage cell- and gene-based therapies to treat patients with cancer. Its pipeline includes Sleeping Beauty TCR-T Targeting neoantigens; Ad-RTS-hlL-12 + veledimex; and Sleeping Beauty CAR-T. The company was founded on September 9, 2003 and is headquartered in Boston, MA.Read More Ad Crypto 101 MediaSHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. ZIOP Stock News HeadlinesFebruary 10, 2024 | investing.comAlx Oncology Holdings (ALXO)January 31, 2024 | reuters.comCG Oncology IncApril 23, 2024 | Banyan Hill Publishing (Ad)Don’t Miss Out on the AI Gold Rush That’s Just Getting Started“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.December 18, 2023 | markets.businessinsider.comWhy Is Alaunos Therapeutics (TCRT) Stock Up 37% Today?September 15, 2023 | newsweek.comWBSPH 2024 - OncologyAugust 29, 2023 | thestreet.comGauging Ziopharm's Chances for Positive Sarcoma Drug Trial ResultsJune 21, 2023 | investing.comZiopharm’s palifosfamide fails in first-line STS…June 15, 2023 | morningstar.comALX Oncology Holdings Inc Ordinary SharesApril 23, 2024 | Banyan Hill Publishing (Ad)Don’t Miss Out on the AI Gold Rush That’s Just Getting Started“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.June 9, 2023 | finance.yahoo.comIntratumoral Cancer Therapies Global Market Report 2023May 11, 2023 | marketwatch.comNatural Killer Cell Therapy Market 2023-2029 New Research Report by Industryreport.coMarch 27, 2023 | marketwatch.comGlobal Drugs for Non-small Cell Lung Cancer Market Size 2023 to 2026 Size and Share Survey ReportMarch 27, 2023 | marketwatch.comChronic Lymphocytic Leukemia Market 2023 Size and Forecast to 2030February 23, 2023 | finance.yahoo.comUSA Community Oncology Services Market Competitor Scenario - Market Positioning And Player-Based Strategies, By The Business Research CompanyFebruary 18, 2023 | finance.yahoo.comVerdi Oncology's Horizon Oncology Announces Agreement with Integra Connect to Bring Value-Based Care to Central IndianaFebruary 18, 2023 | marketwatch.comGlobal Gene Therapy in Oncology Market Size is Booming Across the Globe and Witness Huge Growth by Key Players to 2030 By VMReportsFebruary 18, 2023 | seekingalpha.comiBio shares more than double in value after hours on new immuno-oncology target programJanuary 24, 2023 | marketwatch.comCancer Care Market is booming in near Future 2023-2028January 13, 2023 | finanznachrichten.deNerviano Medical Sciences S.r.l.: Nerviano Medical Sciences Strengthens Executive Team to Maximize IDH1/IDH2 Inhibitor AssetJanuary 12, 2023 | yahoo.comNerviano Medical Sciences Strengthens Executive Team to Maximize IDH1/IDH2 Inhibitor AssetJanuary 5, 2023 | thestreet.comZiopharm Subpar Cancer Therapies Can't Support Lofty Market ValuationNovember 26, 2022 | marketwatch.comCancer Care Market : Share, Industry Size, Opportunities, Analysis and Forecast to 2028 with Top Countries DataNovember 12, 2022 | finance.yahoo.comOncology Clinician-Scientist Jason Luke, MD Named physIQ Medical AdvisorOctober 20, 2022 | finance.yahoo.comGadeta Appoints Scientific Advisory Board and Provides Business UpdateSeptember 27, 2022 | marketwatch.comGlobal Cancer Care Market Size and Scope 2022 Research Report by Consumption, Revenue, Regions, Gross Margin and Forecast to 2026September 24, 2022 | finanznachrichten.deCelyad Oncology SA: Cellistic and Celyad Oncology Announce GMP Cell Therapy Manufacturing Operations TransactionSeptember 7, 2022 | finance.yahoo.comCandel Therapeutics Announces Two Executive Leadership AppointmentsSee More Headlines Receive ZIOP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ZIOPHARM Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/08/2021Today4/22/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:ZIOP CUSIP98973P10 CIK1107421 Webwww.ziopharm.com Phone(617) 259-1970Fax617-241-2855Employees105Year Founded2005Profitability EPS (Most Recent Fiscal Year)($0.43) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-79,980,000.00 Net MarginsN/A Pretax Margin-22,544.97% Return on Equity-92.84% Return on Assets-72.46% Debt Debt-to-Equity Ratio0.18 Current Ratio3.43 Quick Ratio3.43 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.58 per share Price / BookN/AMiscellaneous Outstanding Shares216,146,000Free Float204,906,000Market Cap$187.12 million OptionableOptionable Beta1.71 Social Links Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesKevin S. BoyleChief Executive Officer & DirectorTimothy M. CunninghamChief Financial OfficerLynn M. FerrucciEVP-Human Resources, Administration & ITRaffaele BaffaChief Medical Officer & Head-ResearchEleanor M. de GrootGeneral Manager-Cell Therapy & Executive VPKey CompetitorsRigel PharmaceuticalsNASDAQ:RIGLRegulus TherapeuticsNASDAQ:RGLSVanda PharmaceuticalsNASDAQ:VNDAFoghorn TherapeuticsNASDAQ:FHTXEmergent BioSolutionsNYSE:EBSView All Competitors ZIOP Stock Analysis - Frequently Asked Questions How were ZIOPHARM Oncology's earnings last quarter? ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) issued its quarterly earnings results on Monday, November, 8th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.15) by $0.04. The biotechnology company had revenue of $0.40 million for the quarter. During the same quarter in the previous year, the firm posted ($0.10) earnings per share. What other stocks do shareholders of ZIOPHARM Oncology own? Based on aggregate information from My MarketBeat watchlists, some companies that other ZIOPHARM Oncology investors own include Precigen (PGEN), Gilead Sciences (gild), OPKO Health (OPK), Sangamo Therapeutics (SGMO), Ionis Pharmaceuticals (IONS), Amarin (AMRN), Inovio Pharmaceuticals (INO), Arena Pharmaceuticals (ARNA) and Immunomedics (IMMU). This page (NASDAQ:ZIOP) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersThe A.I. story nobody is telling you (Read ASAP)TradeSmithHealthcare Takes A Big Step Forward With The Help Of AIThe Bull Reporttop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill Publishing[Shocking] Elon Musk’s Plan To End BanksCrypto 101 MediaUrgent Alert: Biden's IRS Targeting Your Money – Act Fast to Protect It!American AlternativeForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ZIOPHARM Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
